Clozapine‐induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine.
Saved in:
| Title: | Clozapine‐induced agranulocytosis in Japan: Changes in leukocyte/neutrophil counts before and after discontinuation of clozapine. |
|---|---|
| Authors: | Matsui, Kentaro (AUTHOR), Ishibashi, Mikiko (AUTHOR), Kawano, Masahiko (AUTHOR), Oshibuchi, Hidehiro (AUTHOR), Ishigooka, Jun (AUTHOR), Nishimura, Katsuji (AUTHOR), Inada, Ken (AUTHOR) |
| Source: | Human Psychopharmacology: Clinical & Experimental. Jul2020, Vol. 35 Issue 4, p1-8. 8p. |
| Subjects: | Agranulocytosis, Leukocyte count, Leukocytes, Patient monitoring, Neutropenia |
| Geographic Terms: | Japan |
| Abstract: | Objective: To determine the prevalence, background factors, and progression of and recovery from clozapine‐induced agranulocytosis in Japan. Methods: Data on treatment‐resistant schizophrenia patients registered with the Clozaril Patient Monitoring Service (CPMS) between July 29, 2009 and January 20, 2016 were extracted. Patients with a neutrophil count <500/mm3 were defined as having agranulocytosis, and those with a leukocyte count <3,000/mm3 or a neutrophil count <1,500/mm3 but not meeting the criteria for agranulocytosis were defined as having leukopenia/neutropenia. Results: Of 3,746 patients, agranulocytosis and leukopenia/neutropenia were observed in 38 (1.0%) and 182 (4.9%) patients, respectively. Age was significantly higher in the agranulocytosis group (p <.001). Decreased leukocyte counts 1 week prior to discontinuation were observed only in the agranulocytosis group. The median number of days to recovery from agranulocytosis and leukopenia/neutropenia was 10 and 4, respectively, with more variation in the latter. Conclusions: Although some patients with leukopenia/neutropenia might carry less pathologic significance, the results of this study reconfirmed the importance of regular blood monitoring for preventing agranulocytosis. [ABSTRACT FROM AUTHOR] |
| Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Objective: To determine the prevalence, background factors, and progression of and recovery from clozapine‐induced agranulocytosis in Japan. Methods: Data on treatment‐resistant schizophrenia patients registered with the Clozaril Patient Monitoring Service (CPMS) between July 29, 2009 and January 20, 2016 were extracted. Patients with a neutrophil count <500/mm3 were defined as having agranulocytosis, and those with a leukocyte count <3,000/mm3 or a neutrophil count <1,500/mm3 but not meeting the criteria for agranulocytosis were defined as having leukopenia/neutropenia. Results: Of 3,746 patients, agranulocytosis and leukopenia/neutropenia were observed in 38 (1.0%) and 182 (4.9%) patients, respectively. Age was significantly higher in the agranulocytosis group (p <.001). Decreased leukocyte counts 1 week prior to discontinuation were observed only in the agranulocytosis group. The median number of days to recovery from agranulocytosis and leukopenia/neutropenia was 10 and 4, respectively, with more variation in the latter. Conclusions: Although some patients with leukopenia/neutropenia might carry less pathologic significance, the results of this study reconfirmed the importance of regular blood monitoring for preventing agranulocytosis. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 08856222 |
| DOI: | 10.1002/hup.2739 |
